DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response

DLBCL细胞在CD19 CAR T细胞治疗后出现，具有交叉抗原耐药性和可预测临床CAR T细胞反应的基因特征。